88100-04-3
Chemical Structure
Notoginsenoside Fa
- CAS No.: 88100-04-3
- Formula:C59H100O27
- Molecular Weight:1241.41
IUPAC Name: 2-((2-(3-((3-((4,5-dihydroxy-6-(hydroxymethyl)-3-((3,4,5-trihydroxytetrahydro-2H-pyran-2-yl)oxy)tetrahydro-2H-pyran-2-yl)oxy)-4,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-12-hydroxy-4,4,8,10,14-pentamethylhexadecahydro-1H-cyclopenta[a]phen
InChIKey: HERICYNRBVMDFO-UHFFFAOYSA-N
SMILES: CC12C3(C(C(O)CC1C4(C(C(C)(C(OC5C(C(C(O)C(CO)O5)O)OC6C(C(C(O)C(CO)O6)O)OC7C(C(C(O)CO7)O)O)CC4)C)CC2)C)C(C(CC/C=C(C)/C)(C)OC8OC(C(O)C(O)C8O)COC9OC(C(O)C(O)C9O)CO)CC3)C
Biological Activity: Notoginsenoside Fa, a protopanaxadiol (ppd)-type saponin isolated from P. notoginseng, could possibly activate and recover the function of degenerated brain[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Notoginsenoside Fa | 99.71% | Notoginsenoside Fa, a protopanaxadiol (ppd)-type saponin isolated from P. notoginseng, could possibly activate and recover the function of degenerated brain. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Notoginsenoside Fa (Standard) | ≥98% | Notoginsenoside Fa (Standard) is the analytical standard of Notoginsenoside Fa. This product is intended for research and analytical applications. Notoginsenoside Fa, a protopanaxadiol (ppd)-type saponin isolated from P. notoginseng, could possibly activate and recover the function of degenerated brain. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Z.M. Qian, et al. Simultaneous determination of nucleobases, nucleosides and saponins in Panax notoginseng using multiple columns high performance liquid chromatography. Journal of Pharmaceutical and Biomedical Analysis 48 (2008) 1361-1367.
- [2]. Tohda C, et al. Abeta(25-35)-induced memory impairment, axonal atrophy, and synaptic loss are ameliorated by M1, A metabolite of protopanaxadiol-type saponins. Neuropsychopharmacology. 2004 May;29(5):860-8. [Content Brief]
